Entresto was the company's top-selling product in 2023, generating sales of around $6B. MSN had been aiming to launch its generic version on Thursday, when a key Novartis patent expired.

A federal judge in New Jersey denied a preliminary injunction sought by Novartis (NYSE:NVS) to block MSN Pharmaceuticals from launching a generic version of the former’s blockbuster heart ...

Securing a decision in its favor before the July deadline would allow Novartis to further delay the rollout of MSN’s Entresto copycat, which is already blocked from launching until at least July ...

A U.S. federal judge rejected Swiss drugmaker Novartis' request for a preliminary injunction to stop MSN Pharmaceuticals from selling a generic version of the blockbuster heart medication Entresto.

Novartis (NVS) stock slips as the company lost its bid to block MSN Pharma's generic Entresto launch after a U.S. judge ruled against its injunction. Read more here.

Novartis loses bid to block US Entresto generic through 2026 By Blake Brittain July 11, 202510:10 AM PDTUpdated July 11, 2025 ...

The patent's pediatric exclusivity period expires in July 2025, Novartis said Monday. It added that were no generic versions of Entresto available in the country.

Novartis reported strong Q4 earnings and sales growth, with CEO Narasimhan reportedly downplaying concerns over Entresto's U.S. patent expiration while projecting continued growth in 2025.

Novartis: Entresto US Patent Upheld By US Court Of Appeals January 13, 2025 — 02:03 am EST Written by RTTNews.com for RTTNews -> ...

Novartis sued, alleging the ANDA directly infringed claims 1–4 of Novartis’ U.S. Patent 8,101,659. The U.S. District Court for the District of Delaware agreed with Novartis that the single ...